Liver fibrogenesis and genetic factors

Clinics and Research in Hepatology and Gastroenterology

Volumn 35, Issue , 2011, Pages S3-S9

  Boursier, Jérôme ^a   Louvet, Alexandre ^b  

^a ANGERS UNIVERSITY HOSPITAL   (France)

^b LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; DISEASE COURSE; GENETIC ASSOCIATION; GENETIC MARKER; GENETIC PREDISPOSITION; GENETICS; HOSPITALIZATION; HUMAN; LIVER CIRRHOSIS; MUTATION; PATHOPHYSIOLOGY; PHENOTYPE; PROGNOSIS; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM;

DISEASE PROGRESSION; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; LIVER CIRRHOSIS; MUTATION; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

MLCS; MLOWN;

EID: 80655147513     PISSN: 22107401     EISSN: 2210741X     Source Type: Journal    
DOI: 10.1016/S2210-7401(11)70002-X     Document Type: Article

References (69)

1. Hernandez-Gea, V., Friedman, S.L., Pathogenesis of Liver Fibrosis. Annu Rev Pathol 28 (2011), 425–456.
2. D'Amico, G., Villanuevas, C., Burroughs, A.K., Dollinger, M.M., Planas, R., Sola, R., Calès, P., et al. Clinical stages of cirrhosis: a multicenter cohort study of 1858 patients. Hepatology, 52, 2010, 329A.
3. de Franchis, R., Dell'Era, A., Non-invasive diagnosis of cirrhosis and the natural history of its complications. Best Pract Res Clin Gastroenterol 21 (2007), 3–18.
4. Poynard, T., Bedossa, P., Opolon, P., Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 349 (1997), 825–832.
5. Thein, H.H., Yi, Q., Dore, G.J., Krahn, M.D., Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology 48 (2008), 418–431.
6. Weber, S.N., Wasmuth, H.E., Liver fibrosis: from animal models to mapping of human risk variants. Best Pract Res Clin Gastroenterol 24 (2010), 635–646.
7. Fischer, H.P., Ortiz-Pallardo, M.E., Ko, Y., Esch, C., Zhou, H., Chronic liver disease in heterozygous alpha1-antitrypsin deficiency PiZ. J Hepatol 33 (2000), 883–892.
8. Patel, K., Norris, S., Lebeck, L., Feng, A., Clare, M., Pianko, S., Portmann, B., et al. HLA class I allelic diversity and progression of fibrosis in patients with chronic hepatitis C. Hepatology 43 (2006), 241–249.
9. Romero-Gomez, M., Montes-Cano, M.A., Otero-Fernandez, M.A., Torres, B., Sanchez-Munoz, D., Aguilar, F., Barroso, N., et al. SLC11A1 promoter gene polymorphisms and fibrosis progression in chronic hepatiti s C. Gut 53 (2004), 446–450.
10. Cho, J.H., Genome-wide association studies: present status and future directions. Gastroenterology 138 (2010), 1668–1672 e1661.
11. Karlsen, T.H., Melum, E., Fran ke, A., The utility of genome-wide association studies in hepatology. Hepatology 51 (2010), 1833–1842.
12. Abiola, O., Angel, J.M., Avner, P., Bachmanov, A.A., Belknap, J.K., Bennett, B., Blankenhorn, E.P., et al. The nature and identification of quantitative trait loci: a community's view. Nat Rev Genet 4 (2003), 911–916.
13. Clouthier, D.E., Comerford, S.A., Hammer, R.E., Hepatic fibrosis, glomerulosclerosis, and a lipodystrophy-like syndrome in PEPCK-TGF-beta1 transgenic mice. J Clin Invest 100 (1997), 2697–2713.
14. Kanzler, S., Lohse, A.W., Keil, A., Henninger, J., Dienes, H.P., Schirmacher, P., Rose-John, S., et al. TGF-beta1 in liver fibrosis: an inducible transgenic mouse model to study liver fibrogenesis. Am J Physiol 276 (1999), G1059–G1068.
15. Czochra, P., Klopcic, B., Meyer, E., Herkel, J., Garcia-Lazaro, J.F., Thieringer, F., Schirmacher, P., et al. Liver fibrosis induced by hepatic overexpression of PDGF-B in transgenic mice. J Hepatol 45 (2006), 419–428.
16. Thieringer, F., Maass, T., Czochra, P., Klopcic, B., Conrad, I., Friebe, D., Schirmacher, P., et al. Spontaneous hepatic fibrosis in transgenic mice overexpressing PDGF-A. Gene 423 (2008), 23–28.
17. Popov, Y., Patsenker, E., Fickert, P., Trauner, M., Schup pan, D., Mdr2 (Abcb4) – /– mice spontaneously develop severe biliary fibrosis via massive dysregulation of pro- and antifibrogenic genes. J Hepatol 43 (2005), 1045–1054.
18. Smit, J.J., Schinkel, A.H., Oude Elferink, R.P., Groen, A.K., Wagenaar, E., van Deemter, L., Mol, C.A., et al. Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease. Cell 75 (1993), 451–462.
19. Mencin, A., Seki, E., Osawa, Y., Kodama, Y., De Minicis, S., Knowles, M., Brenner, D.A., Alpha-1 antitrypsin Z protein (PiZ) increases hepatic fibrosis in a murine model of cholestasis. Hepatology 46 (2007), 1443–1452.
20. Hillebrandt, S., Goos, C., Matern, S., Lam mert, F., Genome-wide analysis of hepatic fibrosis in inbred mice identifies the susceptibility locus Hfib1 on chromosome 15. Gastroenterology 123 (2002), 2041–2051.
21. Hillebrandt, S., Wasmuth, H.E., Weiskirchen, R., Hellerbrand, C., Keppeler, H., Werth, A., Schirin-Sokhan, R., et al. Complement factor 5 is a quantitative trait gene that modifies liver fibrogenesis in mice and humans. Nat Genet 37 (2005), 835–843.
22. Bataller, R., North, K.E., Brenner, D.A., Genetic polymorphisms and the progression of liver fibrosis: a critical appraisal. Hepatology 37 (2003), 493–503.
23. Dongiovanni, P., Valenti, L., Rametta, R., Daly, A.K., Nobili, V., Mozzi, E., Leathart, J.B., et al. Genetic variants regulating insulin receptor signalling are associated with the severity of liver damage in patients with non-alcoholic fatty liver disease. Gut 59 (2010), 267–273.
24. Richardson, M.M., Powell, E.E., Barrie, H.D., Clouston, A.D., Purdie, D.M., Jonsson, J.R., A combination of genetic polymorphisms increases the risk of progressive disease in chronic hepa titis C. J Med Genet, 42, 2005, e45.
25. Frazer, K.A., Ballinger, D.G., Cox, D.R., Hinds, D.A., Stuve, L.L., Gibbs, R.A., Belmont, J.W., et al. A second generation human haplotype map of over 3.1 million SNPs. Nature 449 (2007), 851–861.
26. Barrett, J.C., Cardon, L.R., Evaluating coverage of genome-wide association studies. Nat Genet 38 (2006), 659–662.
27. Moore, J.H., Asselbergs, F.W., Williams, S.M., Bioinformatics challenges for genome-wide association studies. Bioinformatics 26 (2010), 445–455.
28. Manolio, T.A., Genomewide association studies and assessment of the risk of disease. N Engl J Med 363 (2010), 166–176.
29. Hindorff, L.A., Sethupathy, P., Junkins, H.A., Ramos, E.M., Mehta, J.P., Collins, F.S., Manolio, T.A., Potential etiologic and functional implications of genome-wide association loci for human diseases and traits. Proc Natl Acad Sci U S A 106 (2009), 9362–9367.
30. Ku, C.S., Loy, E.Y., Pawitan, Y., Chia, K.S., The pursuit of genomewide association studies: where are we now?. J Hum Genet 55 (2010), 195–206.
31. Huang, H., Shiffman, M.L., Friedman, S., Venkatesh, R., Bzowej, N., Abar, O.T., Rowland, C.M., et al. A 7 gene signature identifies the risk of developing cirrhosis in patients with chronic he patitis C. Hepatology 46 (2007), 297–306.
32. Marcolongo, M., Young, B., Dal Pero, F., Fattovich, G., Peraro, L., Guido, M., Sebastiani, G., et al. A seven-gene signature (cirrhosis risk score) predicts liver fibrosis progression in patients with initially mild chronic h epatitis C. Hepatology 50 (2009), 1038–1044.
33. Pradat, P., Trepo, E., Potthoff, A., Bakshi, R., Young, B., Trepo, C., Lagier, R., et al. The cirrhosis risk score predicts liver fibrosis progression in patients with initially mild chronic hepatitis C. Hepatology 51 (2010), 356–357.
34. Plomin, R., Haworth, C.M., Davis, O.S., Common disorders are quantitative traits. Nat Rev Genet 10 (2009), 872–878.
35. Wei, Z., Wang, K., Qu, H.Q., Zhang, H., Bradfield, J., Kim, C., Frackleton, E., et al. From disease association to risk assessment: an optimistic view from genome-wide association studies on type 1 diabetes. PLoS Genet, 5, 2009, e1000678.
36. Wray, N.R., Goddard, M.E., Visscher, P.M., Prediction of individual genetic risk to disease from genome-wide association studies. Genome Res 17 (2007), 1520–1528.
37. Krawczyk, M., Mullenbach, R., Weber, S.N., Zimmer, V., Lammert, F., Genome-wide association studies and genetic risk assessment of liver diseases. Nat Rev Gastroenterol Hepatol 7 (2010), 669–681.
38. Manolio, T.A., Collins, F.S., Cox, N.J., Goldstein, D.B., Hindorff, L.A., Hunter, D.J., McCarthy, M.I., et al. Finding the missing heritability of complex diseases. Nature 461 (2009), 747–753.
39. Barrett, J.C., Clayton, D.G., Concannon, P., Akolkar, B., Cooper, J.D., Erlich, H.A., Julier, C., et al. Genome-wide association study and meta-analysis find that over 40 loci affect risk of type 1 diabetes. Nat Genet 41 (2009), 703–707.
40. Thomas, D., Gene-environment-wide association studies: emerging approaches. Nat Rev Genet 11 (2010), 259–272.
41. Pradere, J.P., Troeger, J.S., Dapito, D.H., Mencin, A.A., Schwabe, R.F., Toll-like receptor 4 and hepatic fibrogenesis. Semin Liver Dis 30 (2010), 232–244.
42. Schwabe, R.F., Seki, E., Brenner, D.A., Toll-like receptor signaling in the liver. Gastroenterology 130 (2006), 1886–1900.
43. Underhill, D.M., Ozinsky, A., Toll-like receptors: key mediators of microbe detection. Curr Opin Immunol 14 (2002), 103–110.
44. Paik, Y.H., Schwabe, R.F., Bataller, R., Russo, M.P., Jobin, C., Brenner, D.A., Toll-like receptor 4 mediates inflammatory signaling by bacterial lipopolysaccharide in human hepatic stellate cells. Hepatology 37 (2003), 1043–1055.
45. Seki, E., De Minicis, S., Osterreicher, C.H., Kluwe, J., Osawa, Y., Brenner, D.A., Schwabe, R.F., TLR4 enhances TGF-beta signaling and hepatic fibrosis. Nat Med 13 (2007), 1324–1332.
46. Guo, J., Loke, J., Zheng, F., Hong, F., Yea, S., Fukata, M., Tarocchi, M., et al. Functional linkage of cirrhosis-predictive single nucleotide polymorphisms of Toll-like receptor 4 to hepatic stellate cell responses. Hepatology 49 (2009), 960–968.
47. Jagavelu, K., Routray, C., Shergill, U., O'Hara, S.P., Faubion, W., Shah, V.H., Endothelial cell toll-like receptor 4 regulates fibrosis-associated angiogenesis in the liver. Hepatology 52 (2010), 590–601.
48. Krayenbuehl, P.A., Hersberger, M., Truninger, K., Mullhaupt, B., Maly, F.E., Bargetzi, M., Schulthess, G., Toll-like receptor 4 gene polymorphism modulates phenotypic expression in patients with hereditary hemochromatosis. Eur J Gastroenterol Hepatol 22 (2010), 835–841.
49. Li, Y., Chang, M., Abar, O., Garcia, V., Rowland, C., Catanese, J., Ross, D., et al. Multiple variants in toll-like receptor 4 gene modulate risk of liver fibrosis in Caucasians with chronic hepatitis C infection. J Hepatol 51 (2009), 750–757.
50. Guo, J., Friedman, S.L., Toll-like receptor 4 signaling in liver injury and hepatic fibrogenesis. Fibrogenesis Tissue Repair, 3, 2010, 21.
51. Meier, U., Gressner, A.M., Endocrine regulation of energy metabolism: review of pathobiochemical and clinical chemical aspects of leptin, ghrelin, adiponectin, and resistin. Clin Chem 50 (2004), 1511–1525.
52. Moreno, M., Chaves, J.F., Sancho-Bru, P., Ramalho, F., Ramalho, L.N., Mansego, M.L., Ivorra, C., et al. Ghrelin attenuates hepatocellular injury and liver fibrogenesis in rodents and influences fibrosis progression in humans. Hepatology 51 (2010), 974–985.
53. Nagaya, N., Moriya, J., Yasumura, Y., Uematsu, M., Ono, F., Shimizu, W., Ueno, K., et al. Effects of ghrelin administration on left ventricular function, exercise capacity, and muscle wasting in patients with chronic heart failure. Circulation 110 (2004), 3674–3679.
54. Romeo, S., Kozlitina, J., Xing, C., Pertsemlidis, A., Cox, D., Pennacchio, L.A., Boerwinkle, E., et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 40 (2008), 1461–1465.
55. Rotman, Y., Koh, C., Zmuda, J.M., Kleiner, D.E., Liang, T.J., The association of genetic variability in patatin-like phospholipase domain-containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease. Hepatology 52 (2010), 894–903.
56. Santoro, N., Kursawe, R., D'Adamo, E., Dykas, D.J., Zhang, C.K., Bale, A.E., Cali, A.M., et al. A common variant in the patatin-like phospholipase 3 gene (PNPLA3) is associated with fatty liver disease in obese children and adolescents. Hepatology 52 (2010), 1281–1290.
57. Valenti, L., Alisi, A., Galmozzi, E., Bartuli, A., Del Menico, B., Alterio, A., Dongiovanni, P., et al. I148 M patatin-like phospholipase domain-containing 3 gene variant and severity of pediatric nonalcoholic fatty liver disease. Hepatology 52 (2010), 1274–1280.
58. Browning, J.D., Cohen, J.C., Hobbs, H.H., Patatin-like phospholipase domain-containing 3 and the pathogenesis and progression of pediatric nonalcoholic fatty liver disease. Hepatology 52 (2010), 1189–1192.
59. He, S., McPhaul, C., Li, J.Z., Garuti, R., Kinch, L., Grishin, N.V., Cohen, J.C., et al. A sequence variation (I148 M) in PNPLA3 associated with nonalcoholic fatty liver disease disrupts triglyceride hydrolysis. J Biol Chem 285 (2010), 6706–6715.
60. Speliotes, E.K., Yerges-Armstrong, L.M., Wu, J., Hernaez, R., Kim, L.J., Palmer, C., Harris, T.B., et al. Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on serum lipids. Hepatology, 52, 2010, 450A.
61. Valenti, L., Al-Serri, A., Daly, A.K., Galmozzi, E., Rametta, R., Dongiovanni, P., Nobili, V., et al. Homozygosity for the patatin-like phospholipase-3/adiponutrin I148 M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease. Hepatology 51 (2010), 1209–1217.
62. Jou, J., Choi, S.S., Diehl, A.M., Mechanisms of disease progression in nonalcoholic fatty liver disease. Semin Liver Dis 28 (2008), 370–379.
63. Stickel, F., Buch, S., Lau, K., Zu Schwabedissen, H.M., Berg, T., Ridinger, M., Rietschel, M., et al. Genetic variation in the PNPLA3 gene is associated with alcoholic liver injury in caucasians. Hepatology 53 (2011), 86–95.
64. Tian, C., Stokowski, R.P., Kershenobich, D., Ballinger, D.G., Hinds, D.A., Variant in PNPLA3 is associated with alcoholic liver disease. Nat Genet 42 (2010), 21–23.
65. Trépo, E., Gustot, T., Degré, D., Lemmers, A., Verset, L., Demetter, P., Ouziel, R., et al. Common polymorphism in PNPLA3 gene is associated with steatosis and cirrhosis in alcoholic liver disease. Hepatology, 52, 2010, 381A.
66. Dill MT, Duong FH, Vogt JE, Bibert S, Bochud PY, Terracciano L, Papassotiropoulos A, et al. Interferon-Induced Gene Expression Is a Stronger Predictor of Treatment Response than IL28B Genotype in Patients with Hepatitis C. Gastroenterology 2011:in press.
67. Ge, D., Fellay, J., Thompson, A.J., Simon, J.S., Shianna, K.V., Urban, T.J., Heinzen, E.L., et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461 (2009), 399–401.
68. Suppiah, V., Moldovan, M., Ahlenstiel, G., Berg, T., Weltman, M., Abate, M.L., Bassendine, M., et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 41 (2009), 1100–1104.
69. Thompson, A.J., Muir, A.J., Sulkowski, M.S., Ge, D., Fellay, J., Shianna, K.V., Urban, T., et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology 139 (2010), 120–129 e1.